Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiprodil in pediatric GRIN-related neurodevelopmental disorder
2023-509672-42-00Phase 3Authorised
- Sponsor
- GRIN Therapeutics, Inc.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of radiprodil in GRIN-related disorder (6 arms), sponsored by GRIN Therapeutics, Inc. Planned start Feb 2023; status: authorised.
02
Drugs
radiprodil
03
Conditions
GRIN-related disorder
Beyond the preview
Go deeper on 2023-509672-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509672-42-00.